Medical therapy for refractory pituitary adenomas-Reference-Cited by-同舟云学术

Medical therapy for refractory pituitary adenomas

Published:2023-04-28 Issue:3 Volume:26 Page:303-306
ISSN:1386-341X
Container-title:Pituitary
language:en
Short-container-title:Pituitary

Author:

Geer Eliza B.^ORCID

Funder

NIH

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s11102-023-01320-9.pdf

Reference28 articles.

1. Casulari LA et al (2004) Nelson’s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 62(6):300–305

2. Katznelson L (2013) Sustained improvements in plasma ACTH and clinical status in a patient with Nelson’s syndrome treated with pasireotide LAR, a multireceptor somatostatin analog. J Clin Endocrinol Metab 98(5):1803–1807

3. Daniel E et al (2018) A prospective longitudinal study of Pasireotide in Nelson’s syndrome. Pituitary 21(3):247–255

4. Lasolle H et al (2019) Pasireotide: a potential therapeutic alternative for resistant prolactinoma. Ann Endocrinol (Paris) 80(2):84–88

5. Coopmans EC et al (2019) Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma.Eur J Endocrinol, 181(2): p. K21-K27.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 3-DIMENSIONAL AUTOMATIC SEGMENTATION OF PITUARITY TUMOR USING DEEP LEARNING;Kahramanmaraş Sütçü İmam Üniversitesi Mühendislik Bilimleri Dergisi;2024-09-03

2. Refractory pituitary adenomas: preface;Pituitary;2023-06